Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes.
Bell
David S H
DS
Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294, USA.
D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use; D015849:Plasminogen Inactivators / Q000097:blood; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones
D002096:C-Peptide; D007004:Hypoglycemic Agents; D015849:Plasminogen Inactivators; D013844:Thiazoles; D045162:Thiazolidinediones; D008687:Metformin; C089946:2,4-thiazolidinedione